**CLAIMS**

1. A pharmaceutical composition comprising
    a) 0.5-50 mg of a GLP-1 agonist and
    b) 20-800 mg, such as 50-500 mg, of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and
    c) 0.6-20 mg, such as 1-10 mg, lubricant,

    wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w/w %, such as at least 95 w/w % of the excipients of the composition.

2. The pharmaceutical composition according to claim 1, wherein the lubricant is magnesium stearate or glyceryl dibehenate.

3. The pharmaceutical composition according to claim 1 or claim 2 consisting of:
    a) 0.5-50 mg of a GLP-1 agonist,
    b) 20-800 mg, such as 50-500 mg, of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and
    c) at least one 0.6-20 mg, such as 1-10 mg, lubricant.

4. The pharmaceutical composition according to any of the previous claims, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w/w % of the composition.

5. The pharmaceutical composition according to any of the previous claims, wherein the compositions comprises 1-8 mg, such as 2-5 mg or such as 2-3 mg magnesium stearate per 100 mg of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

6. The pharmaceutical composition according to any of the previous claims wherein the GLP-1 agonist is a GLP-1 peptide substituted with a fatty acid or a fatty diacid, such as a GLP-1 agonist selected from the group consisting of: semaglutide, $N^{\varepsilon 26}$-{2-[2-(2-{2-[2-(2-{(S)-4-Carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}-ethoxy)ethoxy]acetylamino}ethoxy)ethoxy]acetyl}, $N^{\varepsilon 37}$-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy)ethoxy]acetylamino}-ethoxy)ethoxy]-acetyl}-[Aib$^{8}$,Arg$^{34}$,Lys$^{37}$]GLP-1(7-37)–peptide (GLP-1 agonist B) and N$^{\varepsilon 27}$-

[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]-amino] ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]-acetyl], $N^{\varepsilon 36}$-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]-amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Lys27, Glu30,Arg34,Lys36]-GLP-1-(7-37)-peptidyl-Glu-Gly (GLP-1 agonist C).

7. The pharmaceutical composition according to any of the previous claims, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

8. The pharmaceutical composition according to any of the previous claims, wherein a dose unit comprises;
    a) 0.5-20 mg of semaglutide,
    b) 50-400 mg of SNAC and
    c) 1-10 mg lubricant.

9. The pharmaceutical composition according to any of the previous claims, wherein a dose unit comprises;
    a) 1-10 mg of semaglutide,
    b) 50-300 mg of SNAC and
    c) 1-10 mg magnesium stearate.

10. The pharmaceutical composition according to any of the previous claims 1-6, wherein a dose unit comprises;
    a) 0.5-20 mg of the GLP-1 agonist C,
    b) 50-400 mg of SNAC and
    c) 1-10 mg lubricant.

11. The pharmaceutical composition according to any of the previous claims 1-6, wherein a dose unit comprises;
    a) 1-10 mg of the GLP-1 agonist C,
    b) 50-300 mg of SNAC and
    c) 1-10 mg magnesium stearate.

12. The pharmaceutical composition according to any of the previous claims, wherein the composition is a solid composition, such as a tablet for oral administration.

13. A pharmaceutical composition according to any of the previous claims for use in medicine.

14. A pharmaceutical composition according to any of the previous claims for use in a method of treatment of diabetes and/or obesity.

~~15. A method of treatment of a subject in need thereof, wherein the method comprises administering a therapeutically active amount of a composition according to any of the previous claims to said subject.~~